| Literature DB >> 30784123 |
Khoirun Nisa1, Sue Yee Lim1,2, Masayoshi Shinohara1, Tatsuyuki Osuga3, Nozomu Yokoyama1,4, Masahiro Tamura1, Noriyuki Nagata1, Kazuyoshi Sasaoka1, Angkhana Dermlim1, Rommaneeya Leela-Arporn1, Tomoya Morita1, Noboru Sasaki1, Keitaro Morishita3, Kensuke Nakamura3,5, Hiroshi Ohta1, Mitsuyoshi Takiguchi1.
Abstract
BACKGROUND: Contrast-enhanced ultrasonography (CEUS) can be used to evaluate intestinal perfusion in healthy dogs. It is helpful for diagnosing and monitoring inflammatory bowel disease in humans and could be useful for dogs with chronic intestinal diseases.Entities:
Keywords: CEUS; enhancement; intestinal diseases; tissue perfusion
Mesh:
Substances:
Year: 2019 PMID: 30784123 PMCID: PMC6430930 DOI: 10.1111/jvim.15432
Source DB: PubMed Journal: J Vet Intern Med ISSN: 0891-6640 Impact factor: 3.333
Figure 1Schematic time‐intensity curve (TIC) describing wash‐in and wash‐out after bolus injection. The arrival time indicates the time point when the intensity was greater than the baseline value followed by a continuous increase. The baseline intensity is defined as the intensity at the arrival time. The time‐to‐peak (TTP) indicates the duration from the first appearance of the contrast agent in the duodenal mucosa until maximum enhancement was reached. The peak intensity (PI) indicates the maximum enhancement after subtracting the baseline intensity. The area under the curve (AUC) indicates the area under the TIC above the baseline intensity calculated from the arrival time until the end of the recording (120 seconds). The wash‐in and wash‐out rates (WiR and WoR, respectively) were determined by performing linear regression for all values from the arrival time to the PI and from the PI to the end of the recording, respectively. MPV, mean pixel values
Signalments, clinicopathologic markers, clinical score, and histopathological score of control, chronic inflammatory enteropathy, and intestinal lymphoma groups
| Variable | Control (n = 14) | Chronic inflammatory enteropathy | Intestinal lymphoma (n = 7) | Overall | |
|---|---|---|---|---|---|
| Remission (n = 16) | Symptomatic (n = 10) | ||||
| Signalment | |||||
| Age (years old) | 8.0 (2.0‐14.0) | 7.0 (5.0‐12.0) | 9.0 (7.0‐13.0) | 10.0 (7.0‐12.0) | .27 (K) |
| Body weight (kg) | 4.0 (1.7‐16.1) | 4.2 (1.7‐11.5) | 3.9 (2.2‐8.2) | 5.7 (4.0‐9.7) | .02 (K) |
| Sex | 2 M, 5 CM, 7 SF | 2 M, 2 F, 7 CM, 5 SF | 1 M, 2 F, 4 CM, 3 SF | 1 M, 4 CM, 2 SF | NE |
| Breed | Chihuahua (4) | Chihuahua (3) | Miniature Dachshund (5) | Miniature Dachshund (3) | NE |
| Boston Terrier (2) | |||||
| Yorkshire Terrier (2) | Boston Terrier (2) | ||||
| Miniature Dachshund (4) | Italian Greyhound (2) | Chihuahua (1) | French Bulldog (1) | ||
| Japanese Spitz (1) | Welsh Corgi (1) | ||||
| Yorkshire Terrier (1) | Jack Russell Terrier (1) | ||||
| Miniature Dachshund (1) | |||||
| Pug (1) | |||||
| Pomeranian (2) | Shiba dog (1) | ||||
| Miniature Schnauzer (1) | |||||
| Toy Poodle (2) | |||||
| Papillon (1) | |||||
| Shih Tzu (1) | |||||
| Miniature Pinscher (1) | Welsh Corgi (1) | ||||
| Mix (1) | |||||
| Clinicopathologic marker | |||||
| Albumin | 2.6 (1.6‐5.1) | 2.7 (1.3‐3.7) | 1.7 (1.2‐3.8) | 1.9 (1.4‐2.7) | .04 (A) |
| CRP | 0.2 (0.0‐12.0) | 0.1 (0.0‐1.8) | 2.0 (0.0‐20.0) | 1.9(0.3‐4.2) | .05 (K) |
| Clinical score | |||||
| CCECAI | NE | 1.5 (0.0‐3.0)a | 6.0 (4.0‐17.0)b | 10.0 (8.0‐18.0)b | <.0001 (K) |
| Histopathological score | |||||
| WSAVA | NE | 3.5 (1.0‐7.0) | 4.5 (1.0‐7.0) | NE | .18 (T) |
Abbreviations: M, Male; F, Female; CM, Castrated male; SF, Spayed female; NE, Not examined; RI, Reference interval; CRP, C‐reactive protein; CCECAI, Canine Chronic Enteropathy Clinical Activity Index; WSAVA, World Small Animal Veterinary Association.
Based on 1‐way analysis of variance (A), Wilcoxon/Kruskal‐Wallis (K), or student's t test (T).
Values are presented as median (range).
Values with different superscript letters indicate significant differences among groups based on post hoc analysis (Tukey‐Kramer or Steel‐Dwass).
B‐mode ultrasound findings of duodenum in control, chronic inflammatory enteropathy, and intestinal lymphoma dogs
| Variable | Control (n = 14) | Chronic inflammatory enteropathy | Intestinal lymphoma (n = 7) | |
|---|---|---|---|---|
| Remission (n = 16) | Symptomatic (n = 10) | |||
| Wall thickness | ||||
| Normal | 14 | 16 | 9 | 4 |
| Mild | 0 | 0 | 1 | 3 |
| Moderate, severe thickening | 0 | 0 | 0 | 0 |
| Wall layering | ||||
| Normal | 12 | 16 | 10 | 4 |
| Present but altered | 2 | 0 | 0 | 3 |
| Effaced | 0 | 0 | 0 | 0 |
| Echogenicity of mucosa | ||||
| Normal | 11 | 4 | 0 | 0 |
| Predominantly hypoechoic | 2 | 7 | 1 | 4 |
| Predominantly hyperechoic | 1 | 5 | 9 | 3 |
| Striation | 1 | 5 | 6 | 2 |
| Corrugation | ||||
| Presence | 2 | 1 | 1 | 5 |
| Absence | 12 | 15 | 9 | 2 |
| Focal or segmental lesion | ||||
| Presence | 0 | 0 | 0 | 0 |
| Absence | 14 | 16 | 10 | 7 |
Figure 2Representative sequential images of the duodenum (dashed line) after contrast injection in dogs in the control (A‐C), remission chronic inflammatory enteropathy (CIE) (D‐F), symptomatic CIE (G‐I), and intestinal lymphoma (J‐L) groups. The duodenum of representative dogs immediately before the arrival time (A, D, G, J), soon after contrast injection (B, E, H, K), and at maximum enhancement (C, F, I, L) is shown. Four regions of interests (ROIs) were drawn in the duodenal mucosa for quantitative analysis (B)
Figure 3The averaged time‐intensity curve (TIC) of the control (n = 14), remission chronic inflammatory enteropathy (CIE, n = 16), symptomatic CIE (n = 10), and intestinal lymphoma groups (n = 7)
Perfusion parameters of control, chronic inflammatory enteropathy, and intestinal lymphoma groups
| Variable | Control (n = 14) | Chronic inflammatory enteropathy | Intestinal lymphoma (n = 7) | Overall | |
|---|---|---|---|---|---|
| Remission (n = 16) | Symptomatic (n = 10) | ||||
| TTP (sec) | 4.0 (3.0‐8.0) | 4.0 (2.0‐7.0) | 6.0 (3.0‐7.0) | 6.0 (3.0‐8.0) | .10 (K) |
| PI (MPV) | 89.9 (68.5‐112.2)a | 90.9 (61.8‐125.9)ab | 105.4 (89.3‐128.8)b | 100.5 (76.7‐132.4)ab | .04 (A) |
| AUC (MPV·sec) | 3448.9 (1559.5‐4736.9)a | 3862.3 (2094.5‐6899.0)a | 4847.9 (3824.3‐8462.8)b | 4343.7 (2526.8‐6237.0)ab | .01 (K) |
| WiR (MPV/sec) | 23.0 (10.8‐31.4) | 24.0 (9.3‐35.5) | 17.8 (13.8‐47.7) | 17.9 (11.7‐29.4) | .23 (K) |
| WoR (MPV/sec) | (−)0.7 (0.5‐0.9) | (−)0.7 (0.5‐0.8) | (−)0.7 (0.5‐1.1) | (−)0.7 (0.6‐1.0) | .53 (K) |
Abbreviations: AUC, area under the curve; MPV, mean pixel value; PI, peak intensity; TTP, time to peak; WiR, wash‐in rate; WoR, wash‐out rate.
Based on 1‐way analysis of variance (A) or Wilcoxon/Kruskal‐Wallis (K).
Values are presented as median (range).
Values with different superscript letters indicate significant differences among groups based on post hoc analysis (Tukey‐Kramer or Steel‐Dwass).
Figure 4Scatter plot of perfusion parameters of the control (n = 14), remission chronic inflammatory enteropathy (Remission CIE, n = 16), symptomatic CIE (Symptomatic CIE, n = 10), and intestinal lymphoma groups (n = 7). Time‐to‐peak (TTP) (A), peak intensity (PI) (B), area under the curve (AUC) (C), wash‐in rate (WiR) (D), wash‐out rate (WoR) (E). The floating bar represents the median. An asterisk (*) indicates a significant difference among groups
Figure 5Correlation between peak intensity (PI) and the canine chronic enteropathy clinical activity index (CCECAI) in the chronic inflammatory enteropathy (CIE) group, including the remission CIE and symptomatic CIE (n = 26) groups. Spearman's rho (r) and the P‐value are indicated